The complement factor H-related proteins

Immunological Reviews

Volumn 274, Issue 1, 2016, Pages 191-201

  Medjeral Thomas, Nicholas ^a   Pickering, Matthew C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

complementinflammation; infection; kidney

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; C REACTIVE PROTEIN; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A; COMPLEMENT FACTOR H; COMPLEMENT FACTOR H RELATED PROTEIN 1; COMPLEMENT FACTOR H RELATED PROTEIN 2; COMPLEMENT FACTOR H RELATED PROTEIN 3; COMPLEMENT FACTOR H RELATED PROTEIN 4; COMPLEMENT FACTOR H RELATED PROTEIN 5; COMPLEMENT MEMBRANE ATTACK COMPLEX; FICOLIN; MANNOSE BINDING LECTIN; PATTERN RECOGNITION RECEPTOR; PENTRAXIN 3; PROPERDIN; PROTEIN; UNCLASSIFIED DRUG; FACTOR H-RELATED PROTEIN 1; PLASMA PROTEIN;

AGE RELATED MACULAR DEGENERATION; AUTOIMMUNE DISEASE; C3 GLOMERULOPATHY; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT DISORDER; COMPLEMENT LECTIN PATHWAY; GLOMERULOPATHY; HEMOLYTIC UREMIC SYNDROME; HOMEOSTASIS; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; INFECTION; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; ANIMAL; AUTOIMMUNITY; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM;

ANIMALS; AUTOIMMUNITY; BLOOD PROTEINS; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT FACTOR H; HOMEOSTASIS; HUMANS; IMMUNITY, INNATE;

EID: 84992472522     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12477     Document Type: Review

References (83)

1. Robson MG, Cook HT, Botto M, et al. Accelerated nephrotoxic nephritis is exacerbated in C1q-deficient mice. J Immunol. 2001;166:6820–6828.
2. Mathern DR, Heeger PS. Molecules great and small: the complement system. Clin J Am Soc Nephrol. 2015;10:1636–1650.
3. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11:785–797.
4. Gaboriaud C, Thielens NM, Gregory LA, Rossi V, Fontecilla-Camps JC, Arlaud GJ. Structure and activation of the C1 complex of complement: unraveling the puzzle. Trends Immunol. 2004;25:368–373.
5. Chen CB, Wallis R. Two mechanisms for mannose-binding protein modulation of the activity of its associated serine proteases. J Biol Chem. 2004;279:26058–26065.
6. Dobó J, Harmat V, Beinrohr L, Sebestyén E, Závodszky P, Gál P. MASP-1, a promiscuous complement protease: structure of its catalytic region reveals the basis of its broad specificity. J Immunol. 2009;183:1207–1214.
7. Bexborn F, Andersson PO, Chen H, Nilsson B, Ekdahl KN. The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb). Mol Immunol. 2008;45:2370–2379.
8. Pangburn MK, Schreiber RD, Müller-Eberhard HJ. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J Exp Med. 1981;154:856–867.
9. Sahu A, Kozel TR, Pangburn MK. Specificity of the thioester-containing reactive site of human C3 and its significance to complement activation. Biochem J. 1994;302(Pt 2):429–436.
10. de Cordoba SR, Tortajada A, Harris CL, Morgan BP. Complement dysregulation and disease: from genes and proteins to diagnostics and drugs. Immunobiology. 2012;217:1034–1046.
11. Fearon DT, Austen KF. Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med. 1975;142:856–863.
12. Spitzer D, Mitchell LM, Atkinson JP, Hourcade DE. Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J Immunol. 2007;179:2600–2608.
13. Muller-Eberhard HJ. The killer molecule of complement. J Invest Dermatol. 1985;85(1 Suppl):47s–52s.
14. Adler S, Baker PJ, Johnson RJ, Ochi RF, Pritzl P, Couser WG. Complement membrane attack complex stimulates production of reactive oxygen metabolites by cultured rat mesangial cells. J Clin Invest. 1986;77:762–767.
15. Rodriguez de Cordoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, Sanchez-Corral P. The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol. 2004;41:355–367.
16. Pangburn MK, Schreiber RD, Muller-Eberhard HJ. Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med. 1977;146:257–270.
17. Weiler JM, Daha MR, Austen KF, Fearon DT. Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci USA. 1976;73:3268–3272.
18. Makou E, Herbert AP, Barlow PN. Functional anatomy of complement factor H. Biochemistry. 2013;52:3949–3962.
19. Schwaeble W, Zwirner J, Schulz TF, Linke RP, Dierich MP, Weiss EH. Human complement factor H: expression of an additional truncated gene product of 43 kDa in human liver. Eur J Immunol. 1987;17:1485–1489.
20. Fontaine M, Demares MJ, Koistinen V, et al. Truncated forms of human complement factor H. Biochem J. 1989;258:927–930.
21. Zipfel PF, Skerka C. FHL-1/reconectin: a human complement and immune regulator with cell-adhesive function. Immunol Today. 1999;20:135–140.
22. Rodriguez de Cordoba S, Rubinstein P. Quantitative variations of the C3b/C4b receptor (CR1) in human erythrocytes are controlled by genes within the regulator of complement activation (RCA) gene cluster. J Exp Med. 1986;164:1274–1283.
23. Diaz-Guillen MA, Rodriguez de Cordoba S, Heine-Suner D. A radiation hybrid map of complement factor H and factor H-related genes. Immunogenetics. 1999;49:549–552.
24. Perez-Caballero D, Gonzalez-Rubio C, Gallardo ME, et al. Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am J Hum Genet. 2001;68:478–484.
25. Holmes LV, Strain L, Staniforth SJ, et al. Determining the population frequency of the CFHR3/CFHR1 deletion at 1q32. PLoS ONE. 2013;8:e60352.
26. Skerka C, Zipfel PF. Complement factor H related proteins in immune diseases. Vaccine. 2008;26(Suppl 8):I9–I14.
27. Oppermann M, Manuelian T, Jozsi M, et al. The C-terminus of complement regulator Factor H mediates target recognition: evidence for a compact conformation of the native protein. Clin Exp Immunol. 2006;144:342–352.
28. Manuelian T, Hellwage J, Meri S, et al. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest. 2003;111:1181–1190.
29. Jozsi M, Zipfel PF. Factor H family proteins and human diseases. Trends Immunol. 2008;29:380–387.
30. Heinen S, Hartmann A, Lauer N, et al. Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood. 2009;114:2439–2447.
31. Timmann C, Leippe M, Horstmann RD. Two major serum components antigenically related to complement factor H are different glycosylation forms of a single protein with no factor H-like complement regulatory functions. J Immunol. 1991;146:1265–1270.
32. Skerka C, Timmann C, Horstmann RD, Zipfel PF. Two additional human serum proteins structurally related to complement factor H. Evidence for a family of factor H-related genes. J Immunol. 1992;148:3313–3318.
33. Skerka C, Horstmann RD, Zipfel PF. Molecular cloning of a human serum protein structurally related to complement factor H. J Biol Chem. 1991;266:12015–12020.
34. Abarrategui-Garrido C, Martinez-Barricarte R, Lopez-Trascasa M, de Cordoba SR, Sanchez-Corral P. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood. 2009;114:4261–4271.
35. Park CT, Wright SD. Plasma lipopolysaccharide-binding protein is found associated with a particle containing apolipoprotein A-I, phospholipid, and factor H-related proteins. J Biol Chem. 1996;271:18054–18060.
36. Skerka C, Chen Q, Fremeaux-Bacchi V, Roumenina LT. Complement factor H related proteins (CFHRs). Mol Immunol. 2013;56:170–180.
37. Goicoechea de Jorge E, Caesar JJ, Malik TH, et al. Dimerization of complement factor H-related proteins modulates complement activation in vivo. Proc Natl Acad Sci USA. 2013;110:4685–4690.
38. Tortajada A, Yebenes H, Abarrategui-Garrido C, et al. C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. J Clin Invest. 2013;123:2434–2446.
39. Barbour TD, Pickering MC, Cook HT. Recent insights into C3 glomerulopathy. Nephrol Dial Transplant. 2013;28:1685–1693.
40. Jozsi M, Tortajada A, Uzonyi B, Goicoechea de Jorge E, Rodriguez de Cordoba S. Factor H-related proteins determine complement-activating surfaces. Trends Immunol. 2015;36:374–384.
41. Fritsche LG, Lauer N, Hartmann A, et al. An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD). Hum Mol Genet. 2010;19:4694–4704.
42. Skerka C, Hellwage J, Weber W, et al. The human factor H-related protein 4 (FHR-4). A novel short consensus repeat-containing protein is associated with human triglyceride-rich lipoproteins. J Biol Chem. 1997;272:5627–5634.
43. Jozsi M, Richter H, Loschmann I, et al. FHR-4A: a new factor H-related protein is encoded by the human FHR-4 gene. Eur J Hum Genet. 2005;13:321–329.
44. McRae JL, Duthy TG, Griggs KM, et al. Human factor H-related protein 5 has cofactor activity, inhibits C3 convertase activity, binds heparin and C-reactive protein, and associates with lipoprotein. J Immunol. 2005;174:6250–6256.
45. Murphy B, Georgiou T, Machet D, Hill P, McRae J. Factor H-related protein-5: a novel component of human glomerular immune deposits. Am J Kidney Dis. 2002;39:24–27.
46. Zipfel PF, Skerka C. Complement factor H and related proteins: an expanding family of complement-regulatory proteins? Immunol Today. 1994;15:121–126.
47. Eberhardt HU, Buhlmann D, Hortschansky P, et al. Human factor H-related protein 2 (CFHR2) regulates complement activation. PLoS ONE. 2013;8:e78617.
48. Hellwage J, Jokiranta TS, Koistinen V, Vaarala O, Meri S, Zipfel PF. Functional properties of complement factor H-related proteins FHR-3 and FHR-4: binding to the C3d region of C3b and differential regulation by heparin. FEBS Lett. 1999;462:345–352.
49. McRae JL, Cowan PJ, Power DA, et al. Human factor H-related protein 5 (FHR-5). A new complement-associated protein. J Biol Chem. 2001;276:6747–6754.
50. Hebecker M, Okemefuna AI, Perkins SJ, Mihlan M, Huber-Lang M, Jozsi M. Molecular basis of C-reactive protein binding and modulation of complement activation by factor H-related protein 4. Mol Immunol. 2010;47:1347–1355.
51. Hebecker M, Jozsi M. Factor H-related protein 4 activates complement by serving as a platform for the assembly of alternative pathway C3 convertase via its interaction with C3b protein. J Biol Chem. 2012;287:19528–19536.
52. Csincsi AI, Kopp A, Zoldi M, et al. Factor H-related protein 5 interacts with pentraxin 3 and the extracellular matrix and modulates complement activation. J Immunol. 2015;194:4963–4973.
53. Mihlan M, Hebecker M, Dahse HM, et al. Human complement factor H-related protein 4 binds and recruits native pentameric C-reactive protein to necrotic cells. Mol Immunol. 2009;46:335–344.
54. Gale DP, de Jorge EG, Cook HT, et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet. 2010;376:794–801.
55. Medjeral-Thomas N, Malik TH, Patel MP, et al. A novel CFHR5 fusion protein causes C3 glomerulopathy in a family without Cypriot ancestry. Kidney Int. 2014;85:933–937.
56. Malik TH, Lavin PJ, Goicoechea de Jorge E, et al. A hybrid CFHR3-1 gene causes familial C3 glomerulopathy. J Am Soc Nephrol. 2012;23:1155–1160.
57. Chen Q, Wiesener M, Eberhardt HU, et al. Complement factor H-related hybrid protein deregulates complement in dense deposit disease. J Clin Invest. 2014;124:145–155.
58. Losse J, Zipfel PF, Jozsi M. Factor H and factor H-related protein 1 bind to human neutrophils via complement receptor 3, mediate attachment to Candida albicans, and enhance neutrophil antimicrobial activity. J Immunol. 2010;184:912–921.
59. Schneider MC, Prosser BE, Caesar JJ, et al. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature. 2009;458:890–893.
60. Caesar JJ, Lavender H, Ward PN, et al. Competition between antagonistic complement factors for a single protein on N. meningitidis rules disease susceptibility. Elife. 2014;3:e04008.
61. Horstmann RD, Sievertsen HJ, Knobloch J, Fischetti VA. Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H. Proc Natl Acad Sci USA. 1988;85:1657–1661.
62. Haupt K, Kraiczy P, Wallich R, Brade V, Skerka C, Zipfel PF. Binding of human factor H-related protein 1 to serum-resistant Borrelia burgdorferi is mediated by borrelial complement regulator-acquiring surface proteins. J Infect Dis. 2007;196:124–133.
63. Verma A, Hellwage J, Artiushin S, et al. LfhA, a novel factor H-binding protein of Leptospira interrogans. Infect Immun. 2006;74:2659–2666.
64. Kunert A, Losse J, Gruszin C, et al. Immune evasion of the human pathogen Pseudomonas aeruginosa: elongation factor Tuf is a factor H and plasminogen binding protein. J Immunol. 2007;179:2979–2988.
65. Poltermann S, Kunert A, von der Heide M, Eck R, Hartmann A, Zipfel PF. Gpm1p is a factor H-, FHL-1-, and plasminogen-binding surface protein of Candida albicans. J Biol Chem. 2007;282:37537–37544.
66. Caprioli J, Noris M, Brioschi S, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108:1267–1279.
67. Heinen S, Sanchez-Corral P, Jackson MS, et al. De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome. Hum Mutat. 2006;27:292–293.
68. Roman-Ortiz E, Mendizabal Oteiza S, Pinto S, Lopez-Trascasa M, Sanchez-Corral P, Rodriguez de Cordoba S. Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH/CFHR1 hybrid gene. Pediatr Nephrol. 2014;29:149–153.
69. Sanchez-Corral P, Gonzalez-Rubio C, Rodriguez de Cordoba S, Lopez-Trascasa M. Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Mol Immunol. 2004;41:81–84.
70. Valoti E, Alberti M, Tortajada A, et al. A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation. J Am Soc Nephrol. 2015;26:209–219.
71. Moore I, Strain L, Pappworth I, et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood. 2010;115:379–387.
72. Jozsi M, Strobel S, Dahse HM, et al. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood. 2007;110:1516–1518.
73. Jodele S, Licht C, Goebel J, et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood. 2013;122:2003–2007.
74. Zhao J, Wu H, Khosravi M, et al. Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet. 2011;7:e1002079.
75. Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science. 2005;15(308):421–424.
76. Hughes AE, Orr N, Esfandiary H, Diaz-Torres M, Goodship T, Chakravarthy U. A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nat Genet. 2006;38:1173–1177.
77. Barbour TD, Ruseva MM, Pickering MC. Update on C3 glomerulopathy. Nephrol Dial Transplant. 2016;31:717–725.
78. Magistroni R, D'Agati VD, Appel GB, Kiryluk K. New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney Int. 2015;88:974–989.
79. Rauterberg EW, Lieberknecht HM, Wingen AM, Ritz E. Complement membrane attack (MAC) in idiopathic IgA-glomerulonephritis. Kidney Int. 1987;31:820–829.
80. Gharavi AG, Kiryluk K, Choi M, et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet. 2011;43:321–327.
81. Kiryluk K, Li Y, Sanna-Cherchi S, et al. Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet. 2012;8:e1002765.
82. Zhu L, Zhai YL, Wang FM, et al. Variants in complement factor H and complement factor H-related protein genes, CFHR3 and CFHR1, affect complement activation in IgA nephropathy. J Am Soc Nephrol. 2015;26:1195–1204.
83. Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol. 2009;9:729–740.